- Multiple hereditary exostosis (MHE), a rare genetic disorder characterized by the growth of multiple benign bone tumors, is gaining increased attention in the Middle East and Africa due to improving diagnostic capabilities, growing patient advocacy, and rising focus on rare disease healthcare needs across the region
- The demand for early diagnosis and advanced treatment options for MHE is driven by increasing awareness among healthcare providers and patients, alongside expanding access to genetic counseling and imaging technologies
- South Africa dominated the Middle East and Africa multiple hereditary exostosis market with the largest revenue share of 28.9% in 2024, supported by its relatively advanced healthcare infrastructure, active research programs on genetic disorders, and the presence of specialized medical institutions catering to rare conditions
- United Arab Emirates (UAE) is expected to be the fastest-growing country in the Middle East and Africa multiple hereditary exostosis market during the forecast period due to rising government healthcare spending, increased medical tourism, and the launch of rare disease registries and precision medicine initiatives
- Sessile segment dominated the Middle East and Africa multiple hereditary exostosis market with a market share of 55.2% in 2024, driven by its higher prevalence in patients and easier detection through standard imaging techniques
